{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:00:42Z","timestamp":1794654042949,"version":"4.9.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Immunol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Long coronavirus disease (COVID) is a heterogeneous clinical condition of uncertain etiology triggered by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we used ultrasensitive approaches to profile the immune system and the plasma proteome in healthy convalescent individuals and individuals with long COVID, spanning geographically independent cohorts from Sweden and the United Kingdom. Symptomatic disease was not consistently associated with quantitative differences in immune cell lineage composition or antiviral T cell immunity. Healthy convalescent individuals nonetheless exhibited higher titers of neutralizing antibodies against SARS-CoV-2 than individuals with long COVID, and extensive phenotypic analyses revealed a subtle increase in the expression of some co-inhibitory receptors, most notably PD-1 and TIM-3, among SARS-CoV-2 nonspike-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in individuals with long COVID. We further identified a shared plasma biomarker signature of disease linking breathlessness with apoptotic inflammatory networks centered on various proteins, including CCL3, CD40, IKBKG, IL-18 and IRAK1, and dysregulated pathways associated with cell cycle progression, lung injury and platelet activation, which could potentially inform the diagnosis and treatment of long COVID.\n                  <\/jats:p>","DOI":"10.1038\/s41590-025-02135-5","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:04:45Z","timestamp":1746169485000},"page":"692-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Identification of soluble biomarkers that associate with distinct manifestations of long COVID"],"prefix":"10.1038","volume":"26","author":[{"given":"Yu","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-4361","authenticated-orcid":false,"given":"Curtis","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-3156","authenticated-orcid":false,"given":"Sarah","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Biteus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habiba","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Dager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sian","family":"Llewellyn-Lacey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9856-2938","authenticated-orcid":false,"given":"Kristin","family":"Ladell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragati S.","family":"Amratia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-2098","authenticated-orcid":false,"given":"Kirsten","family":"Bentley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kollnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mily","family":"Akhirunnesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Julin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Lidman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6799-1182","authenticated-orcid":false,"given":"Richard J.","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6230","authenticated-orcid":false,"given":"Michael J.","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-256X","authenticated-orcid":false,"given":"Helen E.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0633-1719","authenticated-orcid":false,"given":"Marcus","family":"Buggert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9416-2737","authenticated-orcid":false,"given":"David A.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"2135_CR1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/s41591-021-01283-z","volume":"27","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601\u2013615 (2021).","journal-title":"Nat. Med."},{"key":"2135_CR2","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 28, 1706\u20131714 (2022).","journal-title":"Nat. Med."},{"key":"2135_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"2135_CR4","doi-asserted-by":"publisher","first-page":"e86015","DOI":"10.7554\/eLife.86015","volume":"12","author":"B Chen","year":"2023","unstructured":"Chen, B., Julg, B., Mohandas, S. & Bradfute, S. B. RECOVER Mechanistic Pathways Task Force. Viral persistence, reactivation, and mechanisms of long COVID. eLife 12, e86015 (2023).","journal-title":"eLife"},{"key":"2135_CR5","first-page":"36","volume":"7","author":"FH Zadeh","year":"2023","unstructured":"Zadeh, F. H., Wilson, D. R. & Agrawal, D. K. Long COVID: complications, underlying mechanisms, and treatment strategies. Arch. Microbiol. Immunol. 7, 36\u201361 (2023).","journal-title":"Arch. Microbiol. Immunol."},{"key":"2135_CR6","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1080\/07853890.2022.2076901","volume":"54","author":"D Castanares-Zapatero","year":"2022","unstructured":"Castanares-Zapatero, D. et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann. Med. 54, 1473\u20131487 (2022).","journal-title":"Ann. Med."},{"key":"2135_CR7","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","volume":"612","author":"SR Stein","year":"2022","unstructured":"Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758\u2013763 (2022).","journal-title":"Nature"},{"key":"2135_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41590-021-01113-x","volume":"23","author":"C Phetsouphanh","year":"2022","unstructured":"Phetsouphanh, C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 23, 210\u2013216 (2022).","journal-title":"Nat. Immunol."},{"key":"2135_CR9","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/s41590-023-01601-2","volume":"24","author":"AD Proal","year":"2023","unstructured":"Proal, A. D. et al. SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC). Nat. Immunol. 24, 1616\u20131627 (2023).","journal-title":"Nat. Immunol."},{"key":"2135_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cell.2022.01.014","volume":"185","author":"Y Su","year":"2022","unstructured":"Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881\u2013895 (2022).","journal-title":"Cell"},{"key":"2135_CR11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.86002","volume":"12","author":"ZA Sherif","year":"2023","unstructured":"Sherif, Z. A. et al. Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). eLife 12, e86002 (2023).","journal-title":"eLife"},{"key":"2135_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38682-4","volume":"14","author":"A Talla","year":"2023","unstructured":"Talla, A. et al. Persistent serum protein signatures define an inflammatory subcategory of long COVID. Nat. Commun. 14, 3417 (2023).","journal-title":"Nat. Commun."},{"key":"2135_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.781100","volume":"12","author":"K Suhre","year":"2021","unstructured":"Suhre, K. et al. Identification of robust protein associations with COVID-19 disease based on five clinical studies. Front. Immunol. 12, 781100 (2021).","journal-title":"Front. Immunol."},{"key":"2135_CR14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41590-023-01724-6","volume":"25","author":"K Yin","year":"2024","unstructured":"Yin, K. et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol. 25, 218\u2013225 (2024).","journal-title":"Nat. Immunol."},{"key":"2135_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100663","volume":"3","author":"C Schultheiss","year":"2022","unstructured":"Schultheiss, C. et al. The IL-1\u03b2, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 3, 100663 (2022).","journal-title":"Cell Rep. Med."},{"key":"2135_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41586-023-06651-y","volume":"623","author":"J Klein","year":"2023","unstructured":"Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. Nature 623, 139\u2013148 (2023).","journal-title":"Nature"},{"key":"2135_CR17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.medj.2024.01.011","volume":"5","author":"K Baillie","year":"2024","unstructured":"Baillie, K. et al. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med. 5, 239\u2013253 (2024).","journal-title":"Med."},{"key":"2135_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/science.adg7942","volume":"383","author":"C Cervia-Hasler","year":"2024","unstructured":"Cervia-Hasler, C. et al. Persistent complement dysregulation with signs of thromboinflammation in active long COVID. Science 383, eadg7942 (2024).","journal-title":"Science"},{"key":"2135_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1189\/jlb.0208107","volume":"85","author":"PK Chattopadhyay","year":"2009","unstructured":"Chattopadhyay, P. K. et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J. Leukoc. Biol. 85, 88\u201397 (2009).","journal-title":"J. Leukoc. Biol."},{"key":"2135_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163669","volume":"133","author":"MJ Peluso","year":"2023","unstructured":"Peluso, M. J. et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 133, e163669 (2023).","journal-title":"J. Clin. Invest."},{"key":"2135_CR21","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","volume":"23","author":"DM Altmann","year":"2023","unstructured":"Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J. & Boyton, R. J. The immunology of long COVID. Nat. Rev. Immunol. 23, 618\u2013634 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"2135_CR22","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.immuni.2022.07.005","volume":"55","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination. Immunity 55, 1732\u20131746 (2022).","journal-title":"Immunity"},{"key":"2135_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","volume":"28","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med. 28, 472\u2013476 (2022).","journal-title":"Nat. Med."},{"key":"2135_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40460-1","volume":"14","author":"DM Altmann","year":"2023","unstructured":"Altmann, D. M. et al. Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity. Nat. Commun. 14, 5139 (2023).","journal-title":"Nat. Commun."},{"key":"2135_CR25","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168 (2020).","journal-title":"Cell"},{"key":"2135_CR26","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.chom.2023.04.015","volume":"31","author":"S Adamo","year":"2023","unstructured":"Adamo, S. et al. Memory profiles distinguish cross-reactive and virus-specific T cell immunity to mpox. Cell Host Microbe 31, 928\u2013936 (2023).","journal-title":"Cell Host Microbe"},{"key":"2135_CR27","doi-asserted-by":"publisher","first-page":"e1004251","DOI":"10.1371\/journal.ppat.1004251","volume":"10","author":"M Buggert","year":"2014","unstructured":"Buggert, M. et al. T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection. PLoS Pathog. 10, e1004251 (2014).","journal-title":"PLoS Pathog."},{"key":"2135_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21542-4","volume":"12","author":"SB Zaghlool","year":"2021","unstructured":"Zaghlool, S. B. et al. Revealing the role of the human blood plasma proteome in obesity using genetic drivers. Nat. Commun. 12, 1279 (2021).","journal-title":"Nat. Commun."},{"key":"2135_CR29","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/occmed\/kqx063","volume":"67","author":"N Williams","year":"2017","unstructured":"Williams, N. The Borg Rating of Perceived Exertion (RPE) scale. Occup. Med. 67, 404\u2013405 (2017).","journal-title":"Occup. Med."},{"key":"2135_CR30","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-020-2700-3","volume":"588","author":"T Takahashi","year":"2020","unstructured":"Takahashi, T. et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 588, 315\u2013320 (2020).","journal-title":"Nature"},{"key":"2135_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.mayocp.2021.11.033","volume":"97","author":"R Ganesh","year":"2022","unstructured":"Ganesh, R. et al. The female-predominant persistent immune dysregulation of the post-COVID syndrome. Mayo Clin. Proc. 97, 454\u2013464 (2022).","journal-title":"Mayo Clin. Proc."},{"key":"2135_CR32","doi-asserted-by":"publisher","first-page":"611.e9","DOI":"10.1016\/j.cmi.2021.11.002","volume":"28","author":"F Bai","year":"2022","unstructured":"Bai, F. et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin. Microbiol. Infect. 28, 611.e9\u2013611.e16 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"2135_CR33","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41591-022-01810-6","volume":"28","author":"J Choutka","year":"2022","unstructured":"Choutka, J., Jansari, V., Hornig, M. & Iwasaki, A. Unexplained post-acute infection syndromes. Nat. Med. 28, 911\u2013923 (2022).","journal-title":"Nat. Med."},{"key":"2135_CR34","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/s41591-022-01840-0","volume":"28","author":"Z Al-Aly","year":"2022","unstructured":"Al-Aly, Z., Bowe, B. & Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461\u20131467 (2022).","journal-title":"Nat. Med."},{"key":"2135_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1473-3099(23)00684-9","volume":"24","author":"Y Xie","year":"2024","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect. Dis. 24, 239\u2013255 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"2135_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-2600(23)00414-9","volume":"12","author":"M Catala","year":"2024","unstructured":"Catala, M. et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir. Med. 12, 225\u2013236 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2135_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170681","volume":"8","author":"MD Grant","year":"2023","unstructured":"Grant, M. D. et al. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2. JCI Insight 8, e170681 (2023).","journal-title":"JCI Insight"},{"key":"2135_CR38","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74489","volume":"11","author":"CA Fielding","year":"2022","unstructured":"Fielding, C. A. et al. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11, e74489 (2022).","journal-title":"eLife"},{"key":"2135_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848886","volume":"13","author":"M Galan","year":"2022","unstructured":"Galan, M. et al. Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front. Immunol. 13, 848886 (2022).","journal-title":"Front. Immunol."},{"key":"2135_CR40","doi-asserted-by":"publisher","first-page":"e1003773","DOI":"10.1371\/journal.pmed.1003773","volume":"18","author":"M Taquet","year":"2021","unstructured":"Taquet, M. et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 18, e1003773 (2021).","journal-title":"PLoS Med."},{"key":"2135_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101019","volume":"38","author":"HE Davis","year":"2021","unstructured":"Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021).","journal-title":"EClinicalMedicine"},{"key":"2135_CR42","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.dsx.2021.04.007","volume":"15","author":"AV Raveendran","year":"2021","unstructured":"Raveendran, A. V., Jayadevan, R. & Sashidharan, S. Long COVID: an overview. Diabetes Metab. Syndr. 15, 869\u2013875 (2021).","journal-title":"Diabetes Metab. Syndr."},{"key":"2135_CR43","doi-asserted-by":"publisher","first-page":"n1648","DOI":"10.1136\/bmj.n1648","volume":"374","author":"H Crook","year":"2021","unstructured":"Crook, H., Raza, S., Nowell, J., Young, M. & Edison, P. Long COVID\u2014mechanisms, risk factors, and management. BMJ 374, n1648 (2021).","journal-title":"BMJ"},{"key":"2135_CR44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859 (2022).","journal-title":"Cell"},{"key":"2135_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41577-021-00656-2","volume":"22","author":"LR Wong","year":"2022","unstructured":"Wong, L. R. & Perlman, S. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses\u2014are we our own worst enemy? Nat. Rev. Immunol. 22, 47\u201356 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"2135_CR46","first-page":"151544","volume":"6","author":"JK Files","year":"2021","unstructured":"Files, J. K. et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 6, 151544 (2021).","journal-title":"JCI Insight"},{"key":"2135_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109518","volume":"36","author":"MJ Peluso","year":"2021","unstructured":"Peluso, M. J. et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 36, 109518 (2021).","journal-title":"Cell Rep."},{"key":"2135_CR48","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/v13040700","volume":"13","author":"B Silva Andrade","year":"2021","unstructured":"Silva Andrade, B. et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses 13, 700 (2021).","journal-title":"Viruses"},{"key":"2135_CR49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/gutjnl-2021-324280","volume":"71","author":"CCL Cheung","year":"2022","unstructured":"Cheung, C. C. L. et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 71, 226\u2013229 (2022).","journal-title":"Gut"},{"key":"2135_CR50","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1126\/science.abg7113","volume":"373","author":"NA Alwan","year":"2021","unstructured":"Alwan, N. A. The road to addressing long COVID. Science 373, 491\u2013493 (2021).","journal-title":"Science"},{"key":"2135_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1113\/EP090802","volume":"108","author":"R Astin","year":"2023","unstructured":"Astin, R. et al. Long COVID: mechanisms, risk factors and recovery. Exp. Physiol. 108, 12\u201327 (2023).","journal-title":"Exp. Physiol."},{"key":"2135_CR52","doi-asserted-by":"publisher","DOI":"10.1172\/JCI161167","volume":"132","author":"J Ahamed","year":"2022","unstructured":"Ahamed, J. & Laurence, J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J. Clin. Invest. 132, e161167 (2022).","journal-title":"J. Clin. Invest."},{"key":"2135_CR53","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3390\/v15020400","volume":"15","author":"A Vojdani","year":"2023","unstructured":"Vojdani, A., Vojdani, E., Saidara, E. & Maes, M. Persistent SARS-CoV-2 infection, EBV, HHV-6 and other factors may contribute to inflammation and autoimmunity in long COVID. Viruses 15, 400 (2023).","journal-title":"Viruses"},{"key":"2135_CR54","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/pathogens10060763","volume":"10","author":"JE Gold","year":"2021","unstructured":"Gold, J. E., Okyay, R. A., Licht, W. E. & Hurley, D. J. Investigation of long COVID prevalence and its relationship to Epstein\u2013Barr virus reactivation. Pathogens 10, 763 (2021).","journal-title":"Pathogens"},{"key":"2135_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh0687","volume":"8","author":"C Cai","year":"2023","unstructured":"Cai, C. et al. SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19. Sci. Immunol. 8, eadh0687 (2023).","journal-title":"Sci. Immunol."},{"key":"2135_CR56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.it.2022.02.008","volume":"43","author":"MJ Peluso","year":"2022","unstructured":"Peluso, M. J. & Deeks, S. G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 43, 268\u2013270 (2022).","journal-title":"Trends Immunol."},{"key":"2135_CR57","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.immuni.2020.10.008","volume":"53","author":"T Shu","year":"2020","unstructured":"Shu, T. et al. Plasma proteomics identify biomarkers and pathogenesis of COVID-19. Immunity 53, 1108\u20131122 (2020).","journal-title":"Immunity"},{"key":"2135_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28639-4","volume":"13","author":"MAY Al-Nesf","year":"2022","unstructured":"Al-Nesf, M. A. Y. et al. Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications. Nat. Commun. 13, 946 (2022).","journal-title":"Nat. Commun."},{"key":"2135_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104851","volume":"98","author":"X Gu","year":"2023","unstructured":"Gu, X. et al. Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors. EBioMedicine 98, 104851 (2023).","journal-title":"EBioMedicine"},{"key":"2135_CR60","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/infdis\/jiab490","volume":"224","author":"MJ Peluso","year":"2021","unstructured":"Peluso, M. J. et al. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J. Infect. Dis. 224, 1839\u20131848 (2021).","journal-title":"J. Infect. Dis."},{"key":"2135_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12117","volume":"10","author":"B Krishnamachary","year":"2021","unstructured":"Krishnamachary, B. et al. Extracellular vesicle-mediated endothelial apoptosis and EV-associated proteins correlate with COVID-19 disease severity. J. Extracell. Vesicles 10, e12117 (2021).","journal-title":"J. Extracell. Vesicles"},{"key":"2135_CR62","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/s41418-022-00936-x","volume":"29","author":"S Andre","year":"2022","unstructured":"Andre, S. et al. T cell apoptosis characterizes severe COVID-19 disease. Cell Death Differ. 29, 1486\u20131499 (2022).","journal-title":"Cell Death Differ."},{"key":"2135_CR63","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1042\/BCJ20220016","volume":"479","author":"DB Kell","year":"2022","unstructured":"Kell, D. B., Laubscher, G. J. & Pretorius, E. A central role for amyloid fibrin microclots in long COVID\/PASC: origins and therapeutic implications. Biochem. J. 479, 537\u2013559 (2022).","journal-title":"Biochem. J."},{"key":"2135_CR64","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1080\/17474086.2023.2288154","volume":"16","author":"A Boccatonda","year":"2023","unstructured":"Boccatonda, A., Campello, E., Simion, C. & Simioni, P. Long-term hypercoagulability, endotheliopathy and inflammation following acute SARS-CoV-2 infection. Expert Rev. Hematol. 16, 1035\u20131048 (2023).","journal-title":"Expert Rev. Hematol."},{"key":"2135_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04149-9","volume":"21","author":"C Iosef","year":"2023","unstructured":"Iosef, C. et al. Plasma proteome of long-COVID patients indicates HIF-mediated vasculo-proliferative disease with impact on brain and heart function. J. Transl. Med. 21, 377 (2023).","journal-title":"J. Transl. Med."},{"key":"2135_CR66","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41590-023-01538-6","volume":"24","author":"M Buggert","year":"2023","unstructured":"Buggert, M., Price, D. A., Mackay, L. K. & Betts, M. R. Human circulating and tissue-resident memory CD8+ T cells. Nat. Immunol. 24, 1076\u20131086 (2023).","journal-title":"Nat. Immunol."},{"key":"2135_CR67","doi-asserted-by":"publisher","first-page":"e3001091","DOI":"10.1371\/journal.pbio.3001091","volume":"19","author":"SJ Rihn","year":"2021","unstructured":"Rihn, S. J. et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biol. 19, e3001091 (2021).","journal-title":"PLoS Biol."},{"key":"2135_CR68","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jim.2008.07.008","volume":"338","author":"JJ Melenhorst","year":"2008","unstructured":"Melenhorst, J. J. et al. Detection of low avidity CD8+ T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J. Immunol. Methods 338, 31\u201339 (2008).","journal-title":"J. Immunol. Methods"},{"key":"2135_CR69","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1084\/jem.20051357","volume":"202","author":"DA Price","year":"2005","unstructured":"Price, D. A. et al. Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J. Exp. Med. 202, 1349\u20131361 (2005).","journal-title":"J. Exp. Med."},{"key":"2135_CR70","doi-asserted-by":"publisher","first-page":"e139296","DOI":"10.1172\/JCI139296","volume":"131","author":"VM Vlahava","year":"2021","unstructured":"Vlahava, V. M. et al. Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. J. Clin. Invest. 131, e139296 (2021).","journal-title":"J. Clin. Invest."},{"key":"2135_CR71","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","volume":"18","author":"NT Doncheva","year":"2019","unstructured":"Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: network analysis and visualization of proteomics data. J. Proteome Res. 18, 623\u2013632 (2019).","journal-title":"J. Proteome Res."},{"key":"2135_CR72","doi-asserted-by":"publisher","unstructured":"Cai, C., Gao, Y. & Buggert, M. Olink data for \u2018Identification of soluble biomarkers that associate with distinct manifestations of long COVID\u2019. Zenodo https:\/\/doi.org\/10.5281\/zenodo.14772494 (2025).","DOI":"10.5281\/zenodo.14772494"}],"container-title":["Nature Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02135-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:28:02Z","timestamp":1746505682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41590-025-02135-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":72,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2135"],"URL":"https:\/\/doi.org\/10.1038\/s41590-025-02135-5","relation":{},"ISSN":["1529-2908","1529-2916"],"issn-type":[{"value":"1529-2908","type":"print"},{"value":"1529-2916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S. Aleman has received honoraria for educational events and lectures unrelated to this work from Gilead, AbbVie, Biogen and MSD and reports grants from Gilead and AbbVie. M.B. is a consultant for Bristol Myers Squibb, Mabtech, Pfizer, Oxford Immunotec and MSD. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}